Bristol Myers Squibb Getting Close To Lung Cancer Approval For Nivolumab

These developments are encouraging for Bristol-Myers Squibb, which earlier had fast tracked clinical trials of nivolumab due to successful results. Merck has already launched a similar drug this year and has first-mover advantage in the market. However, we believe that the market is big enough to accommodate more players, considering that the price for the drug is going to be high.
Source: Markets